C4 Therapeutics annual ebitda
2019
2020
2021
2022
2023
2024
2025
C4 Therapeutics EBITDA Growth & History (CCCC)
C4 Therapeutics's calculated EBITDA was −$113.3M for fiscal 2025.
View full C4 Therapeutics company overviewC4 Therapeutics annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$113.3M | $4.5M | — |
| 2024 | 2024-12-31 | −$117.8M | $19.4M | — |
| 2023 | 2023-12-31 | −$137.2M | −$9.3M | — |
| 2022 | 2022-12-31 | −$127.9M | −$47.2M | — |
| 2021 | 2021-12-31 | −$80.6M | −$21.8M | — |
| 2020 | 2020-12-31 | −$58.8M | −$25.0M | — |
| 2019 | 2019-12-31 | −$33.9M | — | — |
C4 Therapeutics quarterly ebitda
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$26.1M | $1.8M | — |
| Q1 2026 | 2026-03-31 | −$27.4M | $1.3M | — |
| Q4 2025 | 2025-12-31 | −$22.7M | $14.5M | — |
| Q3 2025 | 2025-09-30 | −$34.0M | −$6.2M | — |
| Q2 2025 | 2025-06-30 | −$27.9M | −$6.9M | — |
| Q1 2025 | 2025-03-31 | −$28.7M | $3.1M | — |
| Q4 2024 | 2024-12-31 | −$37.2M | −$232,000 | — |
| Q3 2024 | 2024-09-30 | −$27.8M | −$441,000 | — |
| Q2 2024 | 2024-06-30 | −$21.0M | $16.1M | — |
| Q1 2024 | 2024-03-31 | −$31.8M | $3.9M | — |
| Q4 2023 | 2023-12-31 | −$37.0M | $775,000 | — |
| Q3 2023 | 2023-09-30 | −$27.4M | $4.7M | — |
| Q2 2023 | 2023-06-30 | −$37.1M | −$10.2M | — |
| Q1 2023 | 2023-03-31 | −$35.7M | −$4.6M | — |
| Q4 2022 | 2022-12-31 | −$37.8M | −$22.8M | — |
| Q3 2022 | 2022-09-30 | −$32.1M | −$8.1M | — |
| Q2 2022 | 2022-06-30 | −$26.9M | −$5.2M | — |
| Q1 2022 | 2022-03-31 | −$31.1M | −$11.0M | — |
| Q4 2021 | 2021-12-31 | −$14.9M | $3.6M | — |
| Q3 2021 | 2021-09-30 | −$23.9M | −$6.0M | — |
| Q2 2021 | 2021-06-30 | −$21.7M | −$11.3M | — |
| Q1 2021 | 2021-03-31 | −$20.1M | −$8.1M | — |
| Q4 2020 | 2020-12-31 | −$18.5M | — | — |
| Q3 2020 | 2020-09-30 | −$17.9M | — | — |
| Q2 2020 | 2020-06-30 | −$10.4M | — | — |
| Q1 2020 | 2020-03-31 | −$11.9M | — | — |
C4 Therapeutics ebitda trends
Over the last five fiscal years, C4 Therapeutics's ebitda decreased from −$58.8M to −$113.3M, a change of −$54.4M. The latest reported quarter, Q2 2026, shows −$26.1M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review C4 Therapeutics source filings ↗Community posts
C4 advances cemsidomide combination testing alongside new biomarker data
C4 Therapeutics ($CCCC) presented new biomarker findings from its cemsidomide program in multiple myeloma, describing immune activation observed with cemsidomide and dexamethasone. It also reported biomarker results from the first two patie ...
